Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Cholesterol Management
Multiple Papers and Presentations Highlight REDUCE-IT and Vascepa ® Potential Mechanisms of Action of Vascepa Becoming Better Understood American Heart Association References REDUCE-IT in Scientific Advisory BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation
View HTML
Toggle Summary Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA
PDUFA Date Extension to End of December 2019 Expected Management to Host Conference Call Today at 7:00 p.m. ET BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced
View HTML
Toggle Summary Amarin Reports Second Quarter 2019 Financial Results and Operational Update
Record Total Revenue of $100.8 Million Achieved in Q2 2019 Commercial Expansion Plans on Track in Anticipation of September 28, 2019 PDUFA Date for Vascepa® If Approved, Vascepa to Become First Prescription Therapy to Treat Patients with Underlying Cardiovascular Risk Beyond Cholesterol Management
View HTML
Toggle Summary Amarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares
BEDMINSTER, N.J., and DUBLIN, Ireland, July 29, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares (“ADSs”), the underwriters of the offering have exercised in
View HTML
Toggle Summary Amarin to Report Second Quarter 2019 Results and Host Conference Call on July 31, 2019
BEDMINSTER, N.J., and DUBLIN, Ireland, July 24, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's
View HTML
Toggle Summary Amarin Prices Public Offering of American Depositary Shares
BEDMINSTER, N.J. and DUBLIN, Ireland, July 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced the pricing of the underwritten public offering of 22,222,223 American Depositary Shares ("ADSs") at a price to the public of $18.00 per ADS.
View HTML
Toggle Summary Amarin Announces $400,000,000 Public Offering of American Depositary Shares
BEDMINSTER, N.J. and DUBLIN, Ireland, July 17, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it has commenced an underwritten public offering of $400,000,000 of its American Depositary Shares pursuant to a shelf registration.
View HTML
Toggle Summary Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance
Record Revenue Achieved in 1H19 Primarily Due to Increased Demand for Vascepa Guidance for Total 2019 Revenue Increased to a Range of $380 to $420 Million from $350 Million Following Unaudited Second Quarter Results Estimated Between $97 and $101 Million, or Between $170 and $174 Million for the
View HTML

Amarin Corporation